問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumbermRNA-1010-P302
Completed

2022-11-21 - 2023-12-20

Phase III

Terminated8

ICD-10J09.X1

Influenza due to identified novel influenza A virus with pneumonia

ICD-10J10.00

Influenza due to other identified influenza virus with unspecified type of pneumonia

ICD-10J10.08

Influenza due to other identified influenza virus with other specified pneumonia

ICD-10J11.00

Influenza due to unidentified influenza virus with unspecified type of pneumonia

ICD-10J11.08

Influenza due to unidentified influenza virus with specified pneumonia

ICD-9487.0

Influenza with pneumonia

  • Trial Applicant

    PAREXEL INTERNATIONAL CO., LTD.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator MING-CHE LIU Division of Urology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Fu-Lun Chen Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Cheng-Hsun Chiu Division of Pediatrics

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Kuo-Chin Huang Division of Family Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Yi-Ching Yang Division of Family Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 王甯祺 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator Wen-Yuan Lin Division of Family Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Principal Investigator 陳垚生 Division of Infectious Disease

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Completed

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    136 participants

  • Global

    22502 participants